Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis
Background No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clari...
Saved in:
| Published in | British journal of cancer Vol. 130; no. 9; pp. 1552 - 1560 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
18.05.2024
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0007-0920 1532-1827 1532-1827 |
| DOI | 10.1038/s41416-024-02647-1 |
Cover
| Abstract | Background
No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.
Methods
Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.
Results
Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (
P
< 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (
P
< 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (
P
= 0.001) and steroid resistance (
P
= 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.
Conclusions
Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis. |
|---|---|
| AbstractList | BackgroundNo specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.MethodsSerum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.ResultsAnti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.ConclusionsAnti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis. No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis. Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients. Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC. Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis. Background No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis. Methods Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients. Results Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls ( P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies ( P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis ( P = 0.001) and steroid resistance ( P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC. Conclusions Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis. No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.BACKGROUNDNo specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies in >90% of patients with ulcerative colitis (UC). Given that a subset of ICI-induced colitis is similar to UC, we aimed to clarify the relationship between such autoantibodies and ICI-induced colitis.Serum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.METHODSSerum anti-integrin αvβ6 autoantibody levels were compared between 26 patients with ICI-induced colitis and 157 controls. Endoscopic images of ICI-induced colitis were centrally reviewed. Characteristics of anti-integrin αvβ6 autoantibodies in the ICI-induced colitis patients were compared with those of UC patients.Anti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.RESULTSAnti-integrin αvβ6 autoantibodies were found in 8/26 (30.8%) patients with ICI-induced colitis and 3/157 (1.9%) controls (P < 0.001). Patients with anti-integrin αvβ6 autoantibodies had significantly more typical UC endoscopic features than those without the autoantibodies (P < 0.001). Anti-integrin αvβ6 autoantibodies in ICI-induced colitis patients were associated with grade ≥3 colitis (P = 0.001) and steroid resistance (P = 0.005). Anti-integrin αvβ6 autoantibody titers correlated with ICI-induced colitis disease activity. Anti-integrin αvβ6 autoantibodies of ICI-induced colitis exhibited similar characteristics to those of UC.Anti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis.CONCLUSIONSAnti-integrin αvβ6 autoantibodies may serve as potential biomarkers for the diagnosis, classification, risk management, and monitoring the disease activity, of ICI-induced colitis. |
| Author | Nishikawa, Yoshihiro Yamamoto, Shuji Takimoto, Ikuhisa Matsumoto, Shimpei Yamazaki, Hajime Okamoto, Norihiro Chikugo, Koki Yoshida, Hiroyuki Kodama, Yuzo Kitamoto, Hiroki Matsumori, Tomoaki Ota, Sakiko Yasuda, Muneji Ooi, Makoto Kakiuchi, Nobuyuki Hayashi, Hidetoshi Hirano, Tomonori Ohno, Kazuya Kuwada, Takeshi Chiba, Tsutomu Kawakami, Hisato Okada, Hirokazu Muramoto, Yuya Nakanishi, Risa Shiokawa, Masahiro Uza, Norimitsu Seno, Hiroshi Okabe, Makoto Nakamura, Takeharu Yokode, Masataka Morita, Toshihiro |
| Author_xml | – sequence: 1 givenname: Masataka orcidid: 0000-0003-0751-0188 surname: Yokode fullname: Yokode, Masataka organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 2 givenname: Masahiro orcidid: 0000-0001-6436-3888 surname: Shiokawa fullname: Shiokawa, Masahiro email: machan@kuhp.kyoto-u.ac.jp organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 3 givenname: Hisato orcidid: 0000-0002-3280-4850 surname: Kawakami fullname: Kawakami, Hisato email: kawakami_h@med.kindai.ac.jp organization: Department of Medical Oncology, Kindai University Faculty of Medicine – sequence: 4 givenname: Takeshi surname: Kuwada fullname: Kuwada, Takeshi organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 5 givenname: Yoshihiro surname: Nishikawa fullname: Nishikawa, Yoshihiro organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 6 givenname: Yuya surname: Muramoto fullname: Muramoto, Yuya organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 7 givenname: Hiroki surname: Kitamoto fullname: Kitamoto, Hiroki organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 8 givenname: Makoto surname: Okabe fullname: Okabe, Makoto organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 9 givenname: Hajime surname: Yamazaki fullname: Yamazaki, Hajime organization: Section of Clinical Epidemiology, Department of Community Medicine, Graduate School of Medicine, Kyoto University – sequence: 10 givenname: Norihiro surname: Okamoto fullname: Okamoto, Norihiro organization: Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine – sequence: 11 givenname: Toshihiro surname: Morita fullname: Morita, Toshihiro organization: Department of Gastroenterology and Hepatology, Kitano Hospital, Tazuke Kofukai Medical Research Institute – sequence: 12 givenname: Kazuya surname: Ohno fullname: Ohno, Kazuya organization: Department of Gastroenterology, Shizuoka General Hospital – sequence: 13 givenname: Risa surname: Nakanishi fullname: Nakanishi, Risa organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 14 givenname: Ikuhisa surname: Takimoto fullname: Takimoto, Ikuhisa organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 15 givenname: Muneji surname: Yasuda fullname: Yasuda, Muneji organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 16 givenname: Koki surname: Chikugo fullname: Chikugo, Koki organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 17 givenname: Shimpei surname: Matsumoto fullname: Matsumoto, Shimpei organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 18 givenname: Hiroyuki surname: Yoshida fullname: Yoshida, Hiroyuki organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 19 givenname: Sakiko surname: Ota fullname: Ota, Sakiko organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 20 givenname: Takeharu surname: Nakamura fullname: Nakamura, Takeharu organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 21 givenname: Hirokazu surname: Okada fullname: Okada, Hirokazu organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 22 givenname: Tomonori surname: Hirano fullname: Hirano, Tomonori organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 23 givenname: Nobuyuki orcidid: 0000-0003-4893-5414 surname: Kakiuchi fullname: Kakiuchi, Nobuyuki organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 24 givenname: Tomoaki surname: Matsumori fullname: Matsumori, Tomoaki organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 25 givenname: Shuji surname: Yamamoto fullname: Yamamoto, Shuji organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 26 givenname: Norimitsu surname: Uza fullname: Uza, Norimitsu organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine – sequence: 27 givenname: Makoto surname: Ooi fullname: Ooi, Makoto organization: Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine – sequence: 28 givenname: Yuzo surname: Kodama fullname: Kodama, Yuzo organization: Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine – sequence: 29 givenname: Tsutomu surname: Chiba fullname: Chiba, Tsutomu organization: Department of Gastroenterology and Hepatology, Kansai Electric Power Hospital – sequence: 30 givenname: Hidetoshi orcidid: 0000-0001-8787-5587 surname: Hayashi fullname: Hayashi, Hidetoshi organization: Department of Medical Oncology, Kindai University Faculty of Medicine – sequence: 31 givenname: Hiroshi surname: Seno fullname: Seno, Hiroshi organization: Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38461170$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UktuFDEUtFAQmQQuwAJZYsOmwb-23SsURfykSGxgbfnXM8702IPtHikH4EBwkJwJD5Phk0UWluXnqnr17DoDJzFFD8BzjF5jROWbwjDDvEOEtcWZ6PAjsMA9JR2WRJyABUJIdGgg6BSclXLdjgOS4gk4pZJxjAVagO8XsYYuxOqXOUR4-2N3-5NDPdek24VJLvgCdfZQw22qvtX0BE1IG53XPsMxZThP1mddw85Dm6ZQQ-mmsPYwbDZzbLWVt-ttai1giKtgQk25NXSz9e5IeAoej3oq_tndfg6-vn_35fJjd_X5w6fLi6vO9rKvHZEjZgOVVnODLSPc2X7AwlhHrPGEumG0dJCUjBoZKrTjbjDcjcgjRLGR9By8PehuZ7PxzrZ5sp7UNoc2z41KOqj_b2JYqWXaKYxRLwnjTeHVnUJO32ZfqtqEYv006ejTXBQZeiYE7vke-vIe9DrNObb5FEVMkl70_d7Si38t_fFy_KIGkAeAzamU7EdlQ23PnfYOw6QwUvs0qEMaVEuD-p0GhRuV3KMe1R8k0QOpNHBc-vzX9gOsXzw5zDs |
| CitedBy_id | crossref_primary_10_1007_s40278_025_78538_2 crossref_primary_10_3389_fimmu_2025_1551445 crossref_primary_10_3390_ijms26051993 crossref_primary_10_26442_26586630_2024_2_202931 crossref_primary_10_1093_ibd_izae263 |
| Cites_doi | 10.1186/s40425-018-0411-1 10.1126/science.aar4060 10.1186/s12876-018-0864-1 10.1016/S0021-9258(18)42622-1 10.1056/NEJM198712243172603 10.1136/gut.49.3.402 10.3399/bjgp16X685645 10.1016/j.ejca.2015.11.016 10.3390/jcm11071881 10.1080/25785826.2019.1580477 10.1074/jbc.M312103200 10.1200/JCO.21.01440 10.1038/s41571-019-0218-0 10.1093/ecco-jcc/jjx008 10.1016/j.annonc.2022.10.001 10.1126/scitranslmed.aaq0997 10.1016/S0092-8674(02)00971-6 10.1016/0092-8674(92)90115-S 10.1016/j.cgh.2017.03.026 10.1002/cbin.10258 10.1093/ibd/izy104 10.1038/s41416-020-0882-y 10.1136/esmoopen-2017-000278 10.1093/ecco-jcc/jjv227 10.1242/jcs.108.6.2241 10.1038/s41591-022-01680-y 10.2174/138945009788680374 10.1053/j.gastro.2021.02.019 10.1016/j.cgh.2015.12.028 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AN0 AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41416-024-02647-1 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database (Proquest) Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Health & Medical Collection (Proquest) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection ProQuest Health & Medical Collection Medical Database Biological Science Database (Proquest) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Central Student PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1532-1827 |
| EndPage | 1560 |
| ExternalDocumentID | PMC11058246 38461170 10_1038_s41416_024_02647_1 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: MEXT | Japan Society for the Promotion of Science (JSPS) grantid: 22J14815 funderid: https://doi.org/10.13039/501100001691 – fundername: the Japanese Society of Gastroenterology – fundername: MEXT | Japan Society for the Promotion of Science (JSPS) grantid: 22J14815 |
| GroupedDBID | --- 0R~ 23N 36B 39C 4.4 406 53G 5GY 5RE 6J9 70F 7RV AACDK AANZL AASML AATNV AAWTL AAYZH AAZLF ABAKF ABLJU ABOCM ABZZP ACAOD ACGFO ACGFS ACKTT ACPRK ACRQY ACZOJ ADBBV ADFRT ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF AOIJS ASPBG AVWKF AXYYD AZFZN BAWUL BENPR BHPHI BKKNO C6C CS3 DNIVK DPUIP DU5 E3Z EAP EBLON EBS EE. EIOEI EMB F5P FDQFY FEDTE FERAY FIGPU FRJ FSGXE GX1 HCIFZ HVGLF HZ~ IH2 IWAJR JSO JZLTJ KQ8 NQJWS O9- OK1 P2P RNT RNTTT ROL RPM SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TR2 W2D WH7 ~02 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AAFWJ AAYXX ABBRH ABDBE ABFSG ABUWG ACMFV ACSTC AEZWR AFDZB AFHIU AFKRA AHWEU AIXLP AN0 ATHPR AYFIA BBNVY BKEYQ BNQBC BPHCQ BVXVI CCPQU CITATION DIK ESX EX3 FYUFA HMCUK HYE M1P M7P NAPCQ PHGZM PHGZT PQQKQ PROAC PSQYO Q2X UKHRP WOW ABRTQ NPM PJZUB PPXIY PQGLB 3V. 7TO 7U9 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS PUEGO 7X8 5PM |
| ID | FETCH-LOGICAL-c585t-28f14938ca6b1c426dc5917bcd2cbe23d9fc39832fa0b37ad6d9b6df0e0031b83 |
| IEDL.DBID | C6C |
| ISSN | 0007-0920 1532-1827 |
| IngestDate | Thu Aug 21 18:34:33 EDT 2025 Fri Sep 05 11:30:51 EDT 2025 Sat Aug 23 14:22:39 EDT 2025 Mon Jul 21 06:03:35 EDT 2025 Thu Apr 24 22:56:15 EDT 2025 Tue Jul 01 04:23:52 EDT 2025 Fri Feb 21 02:39:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c585t-28f14938ca6b1c426dc5917bcd2cbe23d9fc39832fa0b37ad6d9b6df0e0031b83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-8787-5587 0000-0003-4893-5414 0000-0002-3280-4850 0000-0003-0751-0188 0000-0001-6436-3888 |
| OpenAccessLink | https://www.nature.com/articles/s41416-024-02647-1 |
| PMID | 38461170 |
| PQID | 3048257558 |
| PQPubID | 41855 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_11058246 proquest_miscellaneous_2954771566 proquest_journals_3048257558 pubmed_primary_38461170 crossref_citationtrail_10_1038_s41416_024_02647_1 crossref_primary_10_1038_s41416_024_02647_1 springer_journals_10_1038_s41416_024_02647_1 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-05-18 |
| PublicationDateYYYYMMDD | 2024-05-18 |
| PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-18 day: 18 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | British journal of cancer |
| PublicationTitleAbbrev | Br J Cancer |
| PublicationTitleAlternate | Br J Cancer |
| PublicationYear | 2024 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Hynes (CR15) 1992; 69 Turvill, Aghahoseini, Sivarajasingham, Abbas, Choudhry, Polyzois (CR30) 2016; 66 Breuss, Gallo, Delisser, Klimanskaya, Folkesson, Pittet (CR16) 1995; 108 CR19 Tibble, Sigthorsson, Foster, Sherwood, Fagerhol, Bjarnason (CR29) 2001; 49 Rydell, Ekoff, Hellström, Movérare (CR14) 2022; 11 Kuwada, Shiokawa, Kodama, Ota, Kakiuchi, Nannya (CR12) 2021; 160 Abu-Sbeih, Ali, Luo, Qiao, Raju, Wang (CR9) 2018; 6 Haanen, Obeid, Spain, Carbonnel, Wang, Robert (CR5) 2022; 33 Ribas, Wolchok (CR1) 2018; 359 Cheung, Gupta, Olsson-Brown, Subramanian, Sasson, Heseltine (CR28) 2020; 123 Shiokawa, Kodama, Sekiguchi, Kuwada, Tomono, Kuriyama (CR22) 2018; 10 Uzzan, Martin, Mesin, Livanos, Castro-Dopico, Huang (CR13) 2022; 28 Wang, Abu-Sbeih, Mao, Ali, Qiao, Trinh (CR26) 2018; 24 Yamauchi, Araki, Mitsuyama, Tokito, Ishii, Yoshioka (CR10) 2018; 18 Marthey, Mateus, Mussini, Nachury, Nancey, Grange (CR7) 2016; 10 Kikuchi, Sakuraba, Akemoto, Murai, Fukutoku, Asari (CR11) 2019; 42 Yu, Chen, Lu, Wu, Mo, Liu (CR17) 2014; 38 Schneider, Naidoo, Santomasso, Lacchetti, Adkins, Anadkat (CR4) 2021; 39 Busk, Pytela, Sheppard (CR25) 1992; 267 Verschuren, van den Eertwegh, Wonders, Slangen, van Delft, van Bodegraven (CR6) 2016; 14 Weinreb, Simon, Rayhorn, Yang, Leone, Dolinski (CR23) 2004; 279 Schroeder, Tremaine, Ilstrup (CR20) 1987; 317 Martins, Sofiya, Sykiotis, Lamine, Maillard, Fraga (CR3) 2019; 16 Michot, Bigenwald, Champiat, Collins, Carbonnel, Postel-Vinay (CR2) 2016; 54 Kubo, Kato, Mabe (CR8) 2017; 15 Geukes Foppen, Rozeman, van Wilpe, Postma, Snaebjornsson, van Thienen (CR27) 2018; 3 Magro, Gionchetti, Eliakim, Ardizzone, Armuzzi, Barreiro-de Acosta (CR21) 2017; 11 Bandyopadhyay, Raghavan (CR18) 2009; 10 Hynes (CR24) 2002; 110 JM Michot (2647_CR2) 2016; 54 KW Schroeder (2647_CR20) 1987; 317 MH Geukes Foppen (2647_CR27) 2018; 3 H Abu-Sbeih (2647_CR9) 2018; 6 N Rydell (2647_CR14) 2022; 11 VTF Cheung (2647_CR28) 2020; 123 L Marthey (2647_CR7) 2016; 10 T Kuwada (2647_CR12) 2021; 160 J Turvill (2647_CR30) 2016; 66 M Shiokawa (2647_CR22) 2018; 10 BJ Schneider (2647_CR4) 2021; 39 RO Hynes (2647_CR15) 1992; 69 2647_CR19 A Bandyopadhyay (2647_CR18) 2009; 10 RO Hynes (2647_CR24) 2002; 110 R Yamauchi (2647_CR10) 2018; 18 K Kubo (2647_CR8) 2017; 15 Y Yu (2647_CR17) 2014; 38 J Tibble (2647_CR29) 2001; 49 EC Verschuren (2647_CR6) 2016; 14 M Busk (2647_CR25) 1992; 267 A Ribas (2647_CR1) 2018; 359 JM Breuss (2647_CR16) 1995; 108 M Uzzan (2647_CR13) 2022; 28 Y Wang (2647_CR26) 2018; 24 J Haanen (2647_CR5) 2022; 33 H Kikuchi (2647_CR11) 2019; 42 F Martins (2647_CR3) 2019; 16 F Magro (2647_CR21) 2017; 11 PH Weinreb (2647_CR23) 2004; 279 |
| References_xml | – volume: 6 start-page: 95 year: 2018 ident: CR9 article-title: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0411-1 – volume: 359 start-page: 1350 year: 2018 end-page: 5 ident: CR1 article-title: Cancer immunotherapy using checkpoint blockade publication-title: Science doi: 10.1126/science.aar4060 – volume: 18 start-page: 135 year: 2018 ident: CR10 article-title: The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review publication-title: BMC Gastroenterol doi: 10.1186/s12876-018-0864-1 – volume: 267 start-page: 5790 year: 1992 end-page: 6 ident: CR25 article-title: Characterization of the integrin alpha v beta 6 as a fibronectin-binding protein publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)42622-1 – volume: 317 start-page: 1625 year: 1987 end-page: 9 ident: CR20 article-title: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study publication-title: N. Engl J Med doi: 10.1056/NEJM198712243172603 – volume: 49 start-page: 402 year: 2001 end-page: 8 ident: CR29 article-title: Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma publication-title: Gut doi: 10.1136/gut.49.3.402 – volume: 66 start-page: e499 year: 2016 end-page: e506 ident: CR30 article-title: Faecal calprotectin in patients with suspected colorectal cancer: a diagnostic accuracy study publication-title: Br J Gen Pr doi: 10.3399/bjgp16X685645 – volume: 54 start-page: 139 year: 2016 end-page: 48 ident: CR2 article-title: Immune-related adverse events with immune checkpoint blockade: a comprehensive review publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.11.016 – volume: 11 start-page: 1881 year: 2022 ident: CR14 article-title: Measurement of serum IgG Anti-Integrin αvβ6 autoantibodies is a promising tool in the diagnosis of ulcerative colitis publication-title: J Clin Med doi: 10.3390/jcm11071881 – volume: 42 start-page: 39 year: 2019 end-page: 44 ident: CR11 article-title: A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine publication-title: Immunol Med doi: 10.1080/25785826.2019.1580477 – volume: 279 start-page: 17875 year: 2004 end-page: 87 ident: CR23 article-title: Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct ligand-mimetic and nonligand-mimetic classes publication-title: J Biol Chem doi: 10.1074/jbc.M312103200 – volume: 39 start-page: 4073 year: 2021 end-page: 126 ident: CR4 article-title: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update publication-title: J Clin Oncol doi: 10.1200/JCO.21.01440 – volume: 16 start-page: 563 year: 2019 end-page: 80 ident: CR3 article-title: Adverse effects of immune-checkpoint. Inhibitors: epidemiology, management and surveillance publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0218-0 – volume: 11 start-page: 649 year: 2017 end-page: 70 ident: CR21 article-title: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjx008 – volume: 33 start-page: 1217 year: 2022 end-page: 38 ident: CR5 article-title: Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.10.001 – volume: 10 year: 2018 ident: CR22 article-title: Laminin 511 is a target antigen in autoimmune pancreatitis publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaq0997 – ident: CR19 – volume: 110 start-page: 673 year: 2002 end-page: 87 ident: CR24 article-title: Integrins: bidirectional, allosteric signaling machines publication-title: Cell doi: 10.1016/S0092-8674(02)00971-6 – volume: 69 start-page: 11 year: 1992 end-page: 25 ident: CR15 article-title: Integrins: versatility, modulation, and signaling in cell adhesion publication-title: Cell doi: 10.1016/0092-8674(92)90115-S – volume: 15 start-page: A35 year: 2017 end-page: A36 ident: CR8 article-title: Nivolumab-associated colitis mimicking ulcerative colitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.03.026 – volume: 38 start-page: 777 year: 2014 end-page: 81 ident: CR17 article-title: Alphavbeta6 is required in maintaining the intestinal epithelial barrier function publication-title: Cell Bio Int doi: 10.1002/cbin.10258 – volume: 24 start-page: 1695 year: 2018 end-page: 705 ident: CR26 article-title: Endoscopic and histologic features of immune checkpoint inhibitor-related colitis publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izy104 – volume: 123 start-page: 207 year: 2020 end-page: 15 ident: CR28 article-title: Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? publication-title: Br J Cancer doi: 10.1038/s41416-020-0882-y – volume: 3 year: 2018 ident: CR27 article-title: Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management publication-title: ESMO Open doi: 10.1136/esmoopen-2017-000278 – volume: 10 start-page: 395 year: 2016 end-page: 401 ident: CR7 article-title: Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjv227 – volume: 108 start-page: 2241 year: 1995 end-page: 51 ident: CR16 article-title: Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling publication-title: J Cell Sci doi: 10.1242/jcs.108.6.2241 – volume: 28 start-page: 766 year: 2022 end-page: 79 ident: CR13 article-title: Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity publication-title: Nat Med doi: 10.1038/s41591-022-01680-y – volume: 10 start-page: 645 year: 2009 end-page: 52 ident: CR18 article-title: Defining the role of integrin alphavbeta6 in cancer publication-title: Curr Drug Targets doi: 10.2174/138945009788680374 – volume: 160 start-page: 2383 year: 2021 end-page: 94.e21 ident: CR12 article-title: Identification of an anti–Integrin αvβ6 autoantibody in patients with ulcerative colitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.02.019 – volume: 14 start-page: 836 year: 2016 end-page: 42 ident: CR6 article-title: Clinical, endoscopic, and histologic characteristics of Ipilimumab-associated Colitis publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.12.028 – volume: 267 start-page: 5790 year: 1992 ident: 2647_CR25 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)42622-1 – volume: 6 start-page: 95 year: 2018 ident: 2647_CR9 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0411-1 – volume: 10 start-page: 645 year: 2009 ident: 2647_CR18 publication-title: Curr Drug Targets doi: 10.2174/138945009788680374 – volume: 42 start-page: 39 year: 2019 ident: 2647_CR11 publication-title: Immunol Med doi: 10.1080/25785826.2019.1580477 – volume: 279 start-page: 17875 year: 2004 ident: 2647_CR23 publication-title: J Biol Chem doi: 10.1074/jbc.M312103200 – volume: 66 start-page: e499 year: 2016 ident: 2647_CR30 publication-title: Br J Gen Pr doi: 10.3399/bjgp16X685645 – volume: 110 start-page: 673 year: 2002 ident: 2647_CR24 publication-title: Cell doi: 10.1016/S0092-8674(02)00971-6 – volume: 123 start-page: 207 year: 2020 ident: 2647_CR28 publication-title: Br J Cancer doi: 10.1038/s41416-020-0882-y – volume: 3 year: 2018 ident: 2647_CR27 publication-title: ESMO Open doi: 10.1136/esmoopen-2017-000278 – volume: 10 year: 2018 ident: 2647_CR22 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaq0997 – ident: 2647_CR19 – volume: 11 start-page: 1881 year: 2022 ident: 2647_CR14 publication-title: J Clin Med doi: 10.3390/jcm11071881 – volume: 16 start-page: 563 year: 2019 ident: 2647_CR3 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0218-0 – volume: 15 start-page: A35 year: 2017 ident: 2647_CR8 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2017.03.026 – volume: 108 start-page: 2241 year: 1995 ident: 2647_CR16 publication-title: J Cell Sci doi: 10.1242/jcs.108.6.2241 – volume: 69 start-page: 11 year: 1992 ident: 2647_CR15 publication-title: Cell doi: 10.1016/0092-8674(92)90115-S – volume: 33 start-page: 1217 year: 2022 ident: 2647_CR5 publication-title: Ann Oncol doi: 10.1016/j.annonc.2022.10.001 – volume: 10 start-page: 395 year: 2016 ident: 2647_CR7 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjv227 – volume: 11 start-page: 649 year: 2017 ident: 2647_CR21 publication-title: J Crohns Colitis doi: 10.1093/ecco-jcc/jjx008 – volume: 49 start-page: 402 year: 2001 ident: 2647_CR29 publication-title: Gut doi: 10.1136/gut.49.3.402 – volume: 160 start-page: 2383 year: 2021 ident: 2647_CR12 publication-title: Gastroenterology doi: 10.1053/j.gastro.2021.02.019 – volume: 39 start-page: 4073 year: 2021 ident: 2647_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.21.01440 – volume: 359 start-page: 1350 year: 2018 ident: 2647_CR1 publication-title: Science doi: 10.1126/science.aar4060 – volume: 14 start-page: 836 year: 2016 ident: 2647_CR6 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2015.12.028 – volume: 38 start-page: 777 year: 2014 ident: 2647_CR17 publication-title: Cell Bio Int doi: 10.1002/cbin.10258 – volume: 24 start-page: 1695 year: 2018 ident: 2647_CR26 publication-title: Inflamm Bowel Dis doi: 10.1093/ibd/izy104 – volume: 54 start-page: 139 year: 2016 ident: 2647_CR2 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2015.11.016 – volume: 18 start-page: 135 year: 2018 ident: 2647_CR10 publication-title: BMC Gastroenterol doi: 10.1186/s12876-018-0864-1 – volume: 317 start-page: 1625 year: 1987 ident: 2647_CR20 publication-title: N. Engl J Med doi: 10.1056/NEJM198712243172603 – volume: 28 start-page: 766 year: 2022 ident: 2647_CR13 publication-title: Nat Med doi: 10.1038/s41591-022-01680-y |
| SSID | ssj0009087 |
| Score | 2.47784 |
| Snippet | Background
No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6... No specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6 autoantibodies... BackgroundNo specific biomarker for immune checkpoint inhibitor (ICI)-induced colitis has been established. Previously, we identified anti-integrin αvβ6... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1552 |
| SubjectTerms | 631/154/53/2421 631/250/38 Autoantibodies Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research Drug Resistance Endoscopy Epidemiology Immune checkpoint inhibitors Inflammatory bowel disease Molecular Medicine Oncology Ulcerative colitis |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZtAqWXkr7dpkWF3loRW_JDPoUkJIRCQikN5Cb0Mmuy2Nu1t_-gP6j9IflNnbHlXbahOfhi62FpRqMZzegbQj5WlTWJFhkTUqcs1VUFctB7MFWs5KVPy2TA0ru4zM-v0i_X2XU4cOtCWOUkEwdB7VqLZ-QHYHaDMVNkmTxc_GCYNQq9qyGFxkOyCyJYAp_vHp9efv22gd2N5YiaiQdyJY_DtZlYyIMuTUAZYbBHwZOnBUu2t6Y7-ubdsMl_fKfDlnS2R54EXZIejcR_Sh745hl5dBG85c_Jr6Omr9kICFE39Pb3z9s_OdWrvoXprE2LAYRULz3VdNH2GDYEreF9fAzZWVJQZ-lqbv2IDU7tECnXsXl942mN10rg3czbm0ULXdC6mdUGxMMSOnTAL26q8IJcnZ1-PzlnIe0Cs2A79IzLCggkpNW5SSzs4M5mYNQZ67g1ngtXVlaUIAkqHRtRaJe70uSuij1KCCPFS7LTtI1_TWjGY2lQqyitQ5z-0kowmDwU4lrEJo9IMs24sgGTHFNjzNXgGxdSjVRSQCU1UEklEfm0rrMYETnuLb0_EVKF1dmpDS9F5MP6M6wrdJboxrerTqH_syjQuo3Iq5Hu6-4EKG2YsScicosj1gUQs3v7S1PPBuxu0LYyyVNo9PPEPJv_-v8w3tw_jLfkMR8YOWOJ3Cc7_XLl34Gy1Jv3YUX8BQPtFKQ priority: 102 providerName: ProQuest |
| Title | Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis |
| URI | https://link.springer.com/article/10.1038/s41416-024-02647-1 https://www.ncbi.nlm.nih.gov/pubmed/38461170 https://www.proquest.com/docview/3048257558 https://www.proquest.com/docview/2954771566 https://pubmed.ncbi.nlm.nih.gov/PMC11058246 |
| Volume | 130 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NatwwEB7SBEovpf9xmy4q9NaK2pJ_5GO6JIRCQikN7E3oz6zJYi-73r5BHih9kDxTR7K9YZu20IN9sMaSrBmNZjyjTwDvq8roRPGMcqFSmqqqQj3oHLoqRrDSpWUSsPTOL_Kzy_TLLJvtARv3woSk_QBpGdT0mB32aZ0maDpQXFHwytOCosdzINCv81I9zad3QLux6HEy_S-4ksXDRpmYiz_UsbsY3bMw7ydK_hYtDYvQ6RN4PFiP5Ljv71PYc80zeHg-xMefw_Vx09W0h4CoG3J78-P2Z07UpmtxAGvd-pRBolaOKLJsO58ohLX5Hfg-SWdF0IAlm4VxPRo4MSE3bk0X9ZUjtd9Igs_mzlwtW2yC1M281qgQVtigRQmx4wsv4PL05Pv0jA4HLVCD3kJHmaiQJVwYlevE4Jhak6Ebp41lRjvGbVkZXuLcr1SseaFsbkud2yp2XidowV_CftM27hBIxmKhvR1RGuuR-Usj0EVySMQUj3UeQTKOuDQDCrk_DGMhQzScC9lzSSKXZOCSTCL4sH1n2WNw_JP6aGSkHObjWnJUVKicskxE8G5bjDPJh0dU49rNWvqIZ1F4fzaCVz3ft81xNNP8GT0RiB2J2BJ4lO7dkqaeB7RutK8ywVKs9OMoPHf9-vtnvP4_8jfwiAXBzmgijmC_W23cWzSXOj2BB8WswLuYJhM4-Hxy8fXbJMyZX0CHFDw |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtRAEG2FIAEXxBoMARoJTtCK3e2lfUAoCkQTkskpkXIzvVljZWQPYw-ID-B3kOBD8k1UeZnREJFbDr64N9u19CtXdRUhr_Pc6ECJiAmpQhaqPAc96ByYKkby1IVp0ObSGx_Ho9Pw81l0tkF-DWdhMKxy0ImtoraVwX_kO2B2gzGTRJH8MPvKsGoUeleHEhodWxy6H9_BZKvfH3wE-r7hfP_Tyd6I9VUFmAFo3DAuc1hfSKNiHRjYoKyJwGbRxnKjHRc2zY1IgdFz5WuRKBvbVMc29x0KgJYC5r1BboZCxChFcm8VUpL6ssvRib__Uu73h3R8IXfqMADow2BHhCsOExasb4SX0O3lIM1_PLXtBrh_j9ztkSvd7VjtPtlw5QNya9z75h-Sn7tlU7Au_URR0ovf3y7-xFQtmgqIV-gKwxWpmjuq6KxqMEgJZsPT_xggNKcAnulialyXiZyaNi6vZtPi3NECD7HAvYkz57MKlqBFOSk0KKM5LGiBO-0w4BE5vRZyPCabZVW6J4RG3JcaMUxqLFYFSI0E88xBJ66Er2OPBMMXz0yfAR0LcUyz1hMvZNZRKQMqZS2VssAjb5djZl3-jyt7bw-EzHpdUGcrzvXIq2UzSDG6ZlTpqkWdobc1SdCW9shWR_flcgIgItYH8ohc44hlB8wQvt5SFpM2Uzhgu0jyECZ9NzDP6rn-_xpPr36Nl-T26GR8lB0dHB8-I3d4y9QRC-Q22WzmC_ccYFqjX7SyQcmX6xbGvytcUNQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtRAEC2FIEVcEHsMARoJTtAau9tL-4BQlDBKCIk4ECk305s1Vkb2MPaA-AA-CI58RL6Jai8zGiJyy8EXuxe3a-lXruoqgJd5rlUgeUS5kCENZZ6jHrQWTRUtWGrDNGhz6R2fxAen4Yez6GwD_gxnYVxY5aATW0VtKu3-kY_Q7EZjJokiMcr7sIhP--N3s6_UVZByntahnEbHIkf2x3c03-q3h_tI61eMjd9_3jugfYUBqhEmN5SJHN-FCy1jFWjcrIyO0H5R2jCtLOMmzTVPkelz6SueSBObVMUm960TBiU4jnsDbiY8SZx0ib1VeEnqiy5fp_sVmDK_P7DjczGqwwBhEMXdEa84TGiwvileQrqXAzb_8dq2m-H4DtzuUSzZ7djuLmzY8h5sHfd--vvwc7dsCtqloihKcvHr28XvmMhFUyEhC1W50EUi55ZIMqsaF7CEo7lMAC5YaE4QSJPFVNsuKznRbYxeTafFuSWFO9CC9yZWn88qnIIU5aRQqJjmOKFBTjVDhwdwei3keAibZVXabSAR84VyeCbVxlUISLVAU81iIya5r2IPguGLZ7rPhu6Kckyz1ivPRdZRKUMqZS2VssCD18s-sy4XyJWtdwZCZr1eqLMVF3vwYvkYJdq5aWRpq0WdOc9rkji72oNHHd2X03GEi65WkAdijSOWDVy28PUnZTFps4YjzosEC3HQNwPzrN7r_8t4fPUynsMWimH28fDk6AncYi1PRzQQO7DZzBf2KSK2Rj1rRYPAl-uWxb_HiFUK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-integrin+%CE%B1v%CE%B26+autoantibodies+are+a+potential+biomarker+for+ulcerative+colitis-like+immune+checkpoint+inhibitor-induced+colitis&rft.jtitle=British+journal+of+cancer&rft.au=Yokode%2C+Masataka&rft.au=Shiokawa%2C+Masahiro&rft.au=Kawakami%2C+Hisato&rft.au=Kuwada%2C+Takeshi&rft.date=2024-05-18&rft.pub=Nature+Publishing+Group+UK&rft.issn=0007-0920&rft.eissn=1532-1827&rft.volume=130&rft.issue=9&rft.spage=1552&rft.epage=1560&rft_id=info:doi/10.1038%2Fs41416-024-02647-1&rft.externalDocID=10_1038_s41416_024_02647_1 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-0920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-0920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-0920&client=summon |